Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.
Advertisement
Set Alert for Articles By Ian Haydock

Latest From Ian Haydock

Interview: Setting The Course For Takeda’s R&D Future (Part 2)

Dr. Andrew Plump joined Takeda from Sanofi in 2015 as the Japanese company’s chief medical and scientific officer. In his current position, based in the US, he leads the global R&D organization, which has seen much fundamental change over the past 12 months.

Commercial Strategy

Interview: Setting The Course For Takeda’s R&D Future

Dr. Andrew Plump joined Takeda from Sanofi in 2015 as the Japanese company's chief medical and scientific officer. In his current position, based in the US, he leads the global R&D organization, which has seen much fundamental change over the past 18 months.

Commercial Strategy

Otsuka Ties Up With Mylan To Advance MDR-TB Drug In India?

Otsuka, which has been under fire over delayed access to delamanid in India, appears to have allied with Mylan, which has now secured a key clearance for the novel multidrug-resistant TB therapy in the country.

Commercial Market Access

Biological E Taps Takeda Tech For Affordable Combo Vaccines

Takeda is to transfer selected vaccine technologies to an Indian manufacturer to enable the production of affordable combination vaccines for lower income countries, although likely volumes and prices remain unclear for now.

Vaccines Manufacturing

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Deals M & A

Lenvatinib HCC Results Give Sorafenib Cause To REFLECT?

New comparative data released at ASCO reveal the scope of benefit for Eisai's lenvatinib over close competitor sorafenib in the first-line treatment of unresectable hepatocellular carcinoma. But the Eisai drug may face challenges in carving a position in this setting.

Clinical Trials Research & Development
See All
Advertisement
UsernamePublicRestriction

Register